Cost-effectiveness of avelumab for metastatic Merkel cell carcinoma

An article authored by Ash Bullement and Anthony Hatswell has been published in Pharmacoeconomics Open regarding the cost-effectiveness of avelumab for the treatment of metastatic Merkel cell carcinoma.

The analysis provides a summary of the cost-effectiveness model submitted as part of NICE’s technology appraisal of avelumab, including the use of spline-based survival models and time-to-death based utilities.

You can find the open-access article here